PDL BIOPHARMA, INC. Form 8-K September 09, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 9, 2010

PDL BioPharma, Inc. (Exact name of Company as specified in its charter)

000-19756 (Commission File Number)

Delaware (State or Other Jurisdiction of Incorporation)

94-3023969 (I.R.S. Employer Identification No.)

932 Southwood Boulevard Incline Village, Nevada 89451 (Address of principal executive offices, with zip code)

(775) 832-8500 (Company's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

Item 8.01 Other Events.

On September 9, 2010, PDL BioPharma, Inc. issued a press release regarding NASDAQ's establishment of the ex-dividend date of September 13, 2010, for the upcoming special dividend of \$0.50 per share that will be paid on October 1, 2010, to all stockholders of record on September 15, 2010. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description 99.1 Press Release, Dated September 9, 2010

Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC. (Company)

By: /s/ Christine R. Larson

Christine R. Larson

Vice President and Chief Financial

Officer

Dated: September 9, 2010

Edgar Filing: PDL BIOPHARMA, INC. - Form 8-K

EXHIBIT INDEX

Exhibit No. Description 99.1 Press Release, Dated September 9, 2010